66 related articles for article (PubMed ID: 25593346)
1. Complement activation and rituximab distribution in CNS NHL--letter.
Hofer S; Mengele K; Schmitt M; Pestalozzi B; Aebi S
Clin Cancer Res; 2015 Jan; 21(2):490. PubMed ID: 25593346
[No Abstract] [Full Text] [Related]
2. Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma.
Kadoch C; Li J; Wong VS; Chen L; Cha S; Munster P; Lowell CA; Shuman MA; Rubenstein JL
Clin Cancer Res; 2014 Feb; 20(4):1029-41. PubMed ID: 24190981
[TBL] [Abstract][Full Text] [Related]
3. Objective cerebrospinal fluid response to intraventricular rituximab in indolent CNS lymphoma.
Strowd RE; Abuali IA; Grossman SA
CNS Oncol; 2015; 4(3):131-5. PubMed ID: 25905905
[TBL] [Abstract][Full Text] [Related]
4. Secondary central nervous system lymphoma.
Tomita N; Kodama F; Kanamori H; Motomura S; Ishigatsubo Y
Int J Hematol; 2006 Aug; 84(2):128-35. PubMed ID: 16926134
[TBL] [Abstract][Full Text] [Related]
5. Treatment of primary central nervous system lymphoma with induction of complement-dependent cytotoxicity by intraventricular administration of autologous-serum-supplemented rituximab.
Takami A; Hayashi T; Kita D; Nishimura R; Asakura H; Nakao S
Cancer Sci; 2006 Jan; 97(1):80-3. PubMed ID: 16367925
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era.
Sancho JM; Orfao A; Quijano S; García O; Panizo C; Pérez-Ceballos E; Deben G; Salar A; González-Barca E; Alonso N; García-Vela JA; Capote J; Peñalver FJ; Provencio M; Arias J; Plaza J; Caballero D; Morado M; Feliu E; Ribera JM;
Eur J Haematol; 2010 Oct; 85(4):321-8. PubMed ID: 20528905
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous rituximab: a practical approach?
Tobinai K
Lancet Oncol; 2014 Mar; 15(3):254-5. PubMed ID: 24521992
[No Abstract] [Full Text] [Related]
8. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma.
Chamberlain MC
Neurology; 2015 Feb; 84(7):758-9. PubMed ID: 25688152
[No Abstract] [Full Text] [Related]
9. The risk of CNS involvement in aggressive lymphomas in the rituximab era.
Benevolo G; Chiappella A; Vitolo U
Expert Rev Hematol; 2013 Dec; 6(6):643-52. PubMed ID: 24168678
[TBL] [Abstract][Full Text] [Related]
10. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.
Wong ET; Tishler R; Barron L; Wu JK
Cancer; 2004 Jul; 101(1):139-45. PubMed ID: 15221999
[TBL] [Abstract][Full Text] [Related]
11. [Treatment strategy for central nervous system involvement in intravascular large B-cell lymphoma].
Shimada K
Brain Nerve; 2011 May; 63(5):467-72. PubMed ID: 21515926
[TBL] [Abstract][Full Text] [Related]
12. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus meningoencephalitis after rituximab treatment for primary central nervous system lymphoma.
Siakantaris MP; Argyropoulos KV; Ioannou S; Papadopoulou V; Tzeletas G; Tsonis J; Dimitrakopoulou A; Yiannopoulou KG; Pangalis GA; Vaiopoulos G
Neurologist; 2015 Jan; 19(2):35-7. PubMed ID: 25607329
[TBL] [Abstract][Full Text] [Related]
14. Radioimmunotherapy with (131)I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL).
Kang HJ; Lee SS; Kim KM; Choi TH; Cheon GJ; Kim WS; Suh C; Yang SH; Lim SM
Asia Pac J Clin Oncol; 2011 Jun; 7(2):136-45. PubMed ID: 21585693
[TBL] [Abstract][Full Text] [Related]
15. [Medical management of primary central nervous system lymphoma refractory or resistant to standard of care treatment].
Yamanaka R
Brain Nerve; 2009 Oct; 61(10):1155-64. PubMed ID: 19882942
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma.
Rubenstein JL; Fridlyand J; Abrey L; Shen A; Karch J; Wang E; Issa S; Damon L; Prados M; McDermott M; O'Brien J; Haqq C; Shuman M
J Clin Oncol; 2007 Apr; 25(11):1350-6. PubMed ID: 17312328
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study.
Davies A; Merli F; Mihaljevic B; Siritanaratkul N; Solal-Céligny P; Barrett M; Berge C; Bittner B; Boehnke A; McIntyre C; Macdonald D
Lancet Oncol; 2014 Mar; 15(3):343-52. PubMed ID: 24521993
[TBL] [Abstract][Full Text] [Related]
18. Effect of intravitreous rituximab injections in patients with recurrent ocular lesions associated with central nervous system lymphoma.
Ohguro N; Hashida N; Tano Y
Arch Ophthalmol; 2008 Jul; 126(7):1002-3. PubMed ID: 18625954
[No Abstract] [Full Text] [Related]
19. How to Decide Which DLBCL Patients Should Receive CNS Prophylaxis.
Hall KH; Panjic EH; Valla K; Flowers CR; Cohen JB
Oncology (Williston Park); 2018 Jun; 32(6):303-9. PubMed ID: 29940062
[TBL] [Abstract][Full Text] [Related]
20. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
